Ask the Experts: Biosimilars


The entry of biosimilars to the U.S. health care system is raising a lot of questions for pharmacists, health care providers, and patients. Get familiar with the current state of biosimilar approvals and use, and then get answers to your questions during the Q&A.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Describe the regulatory process for the approval of biosimilars and the current state of biosimilar introduction in the United States.
  2. Discuss factors that should be considered by payers and health systems when assessing the use of formulary structures and utilization management strategies for biosimilars.
  3. Compare strategies regarding how to display biologics and biosimilars in electronic ordering, dispensing, and administration systems in order to prevent name confusion and wrong product selection errors. 
  4. Discuss strategies for communicating with patients about biosimilars in order to answer common questions and facilitate appropriate transitions of care.
  5. Summarize the current status of interchangeability and drug substitution practices related to biosimilars, including requirements at the state level.


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

James Stevenson, BPHARM, PHARMD
Steven Lucio, PharmD, BCPS
AVP, Center for Pharmacy Practice Excellence
Learning Level: Level 2
Track: Specialty Pharmacy, Clinical Patient Care and Services
Session Time Slot(s): 
Monday, March 19
1:00 PM - 2:30 PM
Music City Center - Room 104A-B
ACPE Pharmacist: 0202-0000-18-061-L01-P
CEUs Pharmacist: 0.15
Activity Type: